Gene therapies represent a new era of medicine, offering the potential for truly transformational health gains and further benefits for society and health systems. Health Technology Assessment (HTA) of gene therapies can be challenging for a variety of reasons, including uncertainty regarding long-term outcomes, initial assessment of clinical value, assessment of costs and narrow perspectives. These challenges can result in the potential benefits of these therapies being overlooked and undervalued. This symposium will provide an overview of the challenges faced in the HTA of gene therapies and discuss potential solutions to overcome them. Panelists will provide diverse perspectives and practical examples of solution implementation. The recommendations provided by the panel will demonstrate the practical tools available to address the HTA challenges and work towards unlocking the potentially transformational promise of gene therapy for patients and society.